31Jan

FDA grants de novo designation for OGT’s AML/MDS FISH probes

CYTOCELL-ogt

Oxford, UK – 30th January 2019. Oxford Gene Technology (OGT), The Molecular Genetics Company, has been granted de novo classification by the US Food and Drug Administration (FDA) for eight Cytocell Aquarius® Haematology fluorescence in situ hybridisation (FISH) probes for acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). The probes form the largest FDA-cleared in vitro diagnostic (IVD)* FISH probe range for AML and MDS on the market and will address a substantial proportion of diagnostic laboratory haematological FISH testing. The cleared probes will significantly reduce the level of validation required in laboratories and provide accurate, easy-to-interpret detection of chromosomal rearrangements reported in AML and MDS. The full list of FDA-cleared Cytocell Aquarius FISH probes is:

  • AML1/ETO (RUNX1/RUNX1T1) Translocation, Dual Fusion
  • CBFβ (CBFB)/MYH11 Translocation, Dual Fusion
  • Del(5q) Deletion
  • Del(7q) Deletion
  • Del(20q) Deletion
  • EVI1 (MECOM) Breakapart
  • MLL (KMT2A) Breakapart
  • P53 (TP53) Deletion

The probes are supplied pre-mixed and ready-to-use as part of a complete kit including DAPI, detailed protocols and signal pattern analysis guidelines which streamlines processing and minimises errors – delivering increased convenience and reliable results. Bright, tight, and high-intensity signals with excellent contrast all simplify analyses for confident results, while decreasing retest rates. All Cytocell FISH probe users also benefit from OGT’s renowned expert technical support, enabling laboratories to remain focused on delivering high quality, rapid results to their patients.

“We’re delighted to bring our comprehensive range of FDA-cleared AML and MDS FISH probes to market”, commented Steve Chatters, Director of Medical Affairs at Oxford Gene Technology. “The rigorous FDA de novo pathway requires submission of extensive clinical and performance data from multiple sites, along with robust evidence of the safety and effectiveness of the probes. What this means for customers, particularly in the US, is a significant reduction in the validation burden and immediate access to a range of high-quality IVD probes covering a comprehensive set of rearrangements. Our customers will be able to easily and accurately detect pertinent chromosomal rearrangements in fixed bone marrow specimens without needing to complete lengthy validations for every probe prior to use.”

Dr John Anson, CEO at OGT added, “Gaining FDA clearance for this range of probes is a real milestone for OGT and our customers, demonstrating our continued commitment to developing and providing molecular diagnostic solutions as part of Sysmex. We see FISH technology very much as a long-term diagnostic solution and we are committed to continuing to expand the Cytocell portfolio with new diagnostic products. This is a significant step towards achieving that goal, immediately benefiting our customers by providing access to the largest range of FDA-cleared FISH probes for AML and MDS currently on the market.”

For more information please visit www.cytocell.com.

Intended Use

The Cytocell Aquarius AML/MDS range of FISH probe test kits are fluorescence in situ hybridization (FISH) tests used to detect common chromosomal rearrangements in fixed bone marrow specimens from patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The tests are indicated for the characterization of patient specimens consistent with World Health Organization guidelines for Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised Edition 4) and in conjunction with other clinicopathological criteria. The assay results are to be interpreted by a qualified pathologist or cytogeneticist. The tests are not intended for use as a stand-alone diagnostic, disease screening, or as a companion diagnostic.

Refer to individual test kit pack insert for the specific intended use and limitations.

For In Vitro Diagnostic Use. RX Only

For further information, please contact:

Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.

T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684

E: contact@ogt.com ; W: www.ogt.com ; Twitter: @OxfordGeneTech

Related

OGT unveils reliable somatic CNV detection for CLL with new NGS panel

SureSeq™ CLL + CNV - comprehensive CLL genomic profiling from a single assay

Read More >

BBI Solutions & Dr C. Sturgeon consider International Standards for Cancer Biomarkers

Dr Catharine Sturgeon will be presenting her case for an international effort to align manufacturer’...

Read More >

SpeeDx receives CE-IVD mark for multiplex PlexPCR® VHS test for VZV, herpes and syphilis

SYDNEY, AUSTRALIA–(October 25, 2017). SpeeDx Pty. Ltd. has announced that it has received CE-IVD ma...

Read More >

BBI Solutions Increases Capacity for Cell Culture Native Human Transferrin Production

BBI Solutions (BBI) has invested into its facilities and resource in order to increase the capacity ...

Read More >

EKF Diagnostics opens new R&D facility in UK

Special Projects Laboratory opened in EKF’s Cardiff HQ to develop new applications in non-core mark...

Read More >

NEW TEST COULD REVOLUTIONISE THE DIAGNOSIS OF ‘SUPERBUGS’

A new exhibition at the Science Museum, London will feature an invention from the Oxford area which ...

Read More >